Startups channel feed

Ace­po­di­a's off-the-shelf cell ther­a­pies get an­oth­er $100M for on­col­o­gy tri­als

4 hours ago
Financing
Cell/Gene Tx

Ex­clu­sive: With $8M, neu­ro start­up Mod­u­lo Bio emerges to test small mol­e­cules for ALS, de­men­tia in CEO’s per­son­al mis­sion

5 days ago
Financing
AI

Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

Last week
Financing

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

Last week
Financing
R&D

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

2 weeks ago
Financing

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

2 weeks ago
Cell/Gene Tx

Chas­ing the KRAS field, Quan­ta Ther­a­peu­tics bags $50M for two 2024 clin­i­cal tri­als

3 weeks ago
Financing

Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

3 weeks ago
Financing
R&D

Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

3 weeks ago
Financing

SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

3 weeks ago
Deals
Cell/Gene Tx

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

3 weeks ago
Deals
Cell/Gene Tx

On a per­son­al mis­sion for his daugh­ter, Paul Bres­ge launch­es an­oth­er eye dis­ease biotech with $100M for Ray Ther­a­peu­tics

3 weeks ago
Financing
Cell/Gene Tx

Metaphore Biotech­nolo­gies seeks to mim­ic na­ture with $50M for au­toim­mune, im­munol­o­gy drugs out of Flag­ship

3 weeks ago
Financing

Bel­gian biotech Du­a­lyx en­ters Treg field with $44M for 2024 clin­i­cal en­try

4 weeks ago
Financing

From 5AM's nest, neu­ro­science start­up Nido Bio­sciences launch­es with $109M and PhI un­der­way

4 weeks ago
Financing

New blood and cell ther­a­py-fo­cused ven­ture fund emerges with $50M and a Jen­nifer Doud­na spin­out in tow

4 weeks ago
Financing
Cell/Gene Tx

French biotech jumps in­to type 1 di­a­betes space with $30M Se­ries A round

4 weeks ago
Financing

Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

4 weeks ago
Deals

CRISPR uni­corn Mam­moth backs off di­ag­nos­tics re­search, lay­ing off 35 on test­ing team to fo­cus on ther­a­peu­tics

5 weeks ago
Cell/Gene Tx

Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Last month
Financing

Ace­lyrin's IPO is an 'N of 1', in­dus­try in­sid­ers say, as 50+ biotechs are still wait­ing for their mo­ment on the mar­kets

Last month
Financing

Re­verse merg­ers say hey as biotechs trade low, hunt for al­ter­na­tives and launch few IPOs

Last month
Financing
Deals

Cowen, Long­wood add $735M to bio­phar­ma's pool of mon­ey

Last month
Financing

Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

Last month
Deals
1234 Next page Last page
A service from the Financial Times